{
    "2021-06-29": [
        [
            {
                "time": "2021-06-29",
                "original_text": "晚间重要公告2021年6月29日星期二",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "分红",
                        "研发",
                        "沪股通",
                        "临床试验"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-28",
                "original_text": "A股融资融券日报：两融余额增加94.84亿元（6月28日）",
                "features": {
                    "keywords": [
                        "两融余额",
                        "增加",
                        "趋势性投资"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-29",
                "original_text": "恒瑞医药子公司HR19034滴眼液临床试验获批",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "HR19034",
                        "滴眼液",
                        "临床试验",
                        "批准通知书"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-06-29",
                "original_text": "恒瑞医药碘克沙醇未中标会影响产品销售",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "碘克沙醇",
                        "未中标",
                        "销售影响"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-06-29",
                "original_text": "政策重拳击中，药茅光彩褪色，恒瑞医药内外交困",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "政策压力",
                        "内外交困"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-06-29",
                "original_text": "医药生物行业中期投资策略报告：拥抱新兴产业方向，把握价值低估标的",
                "features": {
                    "keywords": [
                        "医药生物",
                        "投资策略",
                        "新兴产业",
                        "价值低估"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-06-29",
                "original_text": "医药生物行业周观点：集采陆续落地，政策压力不减",
                "features": {
                    "keywords": [
                        "医药生物",
                        "集采",
                        "政策压力"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}